China issues its first prescription for an approved hemophilia B gene-replacement therapy
Now Possible · Friday, 11 September 2026
Why it matters
This is a documented move for a gene therapy from approval into actual treatment in China, replacing the established pattern of dozens to more than 100 factor-infusion punctures per year with a one-time administration for the first treated patient. Accessibility is still limited: broader use depends on local supplementary insurance and further follow-up, with no evidence here that ordinary patients nationwide can yet afford or obtain it.
What happened
China’s first prescription for the approved gene-replacement drug Hemgenix-like therapy “Xinjiu Ning” (etranacogene dezaparvovec, 波哌达可基注射液) was issued at the Chinese Academy of Medical Sciences Institute of Hematology. The first patient’s factor IX activity rose substantially to the level targeted for bleeding prevention after a single intravenous treatment; doctors are continuing to monitor efficacy and safety, so this is an initial patient result rather than proof of durable benefit across patients. The drug is listed in supplementary “Huiminbao” insurance programs in Beijing, Shanghai, Chongqing and Jiangxi, but the article gives no price and does not establish nationwide reimbursement or routine access.
Players & places
- China
- Beijing
- Shanghai
- Chongqing
- Chinese Academy of Medical Sciences Institute of Hematology
- Xinnian Pharmaceutical